AU784293B2 - Human P53 mutations and a genetic system in yeast for functional indentification of human P53 mutations - Google Patents
Human P53 mutations and a genetic system in yeast for functional indentification of human P53 mutations Download PDFInfo
- Publication number
- AU784293B2 AU784293B2 AU62395/00A AU6239500A AU784293B2 AU 784293 B2 AU784293 B2 AU 784293B2 AU 62395/00 A AU62395/00 A AU 62395/00A AU 6239500 A AU6239500 A AU 6239500A AU 784293 B2 AU784293 B2 AU 784293B2
- Authority
- AU
- Australia
- Prior art keywords
- human
- mutation
- colonies
- nucleic acid
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000035772 mutation Effects 0.000 title claims description 376
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims description 141
- 230000002068 genetic effect Effects 0.000 title description 2
- 101100462513 Homo sapiens TP53 gene Proteins 0.000 title 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 837
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 834
- 102000039446 nucleic acids Human genes 0.000 claims description 179
- 108020004707 nucleic acids Proteins 0.000 claims description 179
- 150000007523 nucleic acids Chemical class 0.000 claims description 179
- 210000004027 cell Anatomy 0.000 claims description 176
- 230000002588 toxic effect Effects 0.000 claims description 163
- 231100000331 toxic Toxicity 0.000 claims description 162
- 229930182830 galactose Natural products 0.000 claims description 150
- 230000014509 gene expression Effects 0.000 claims description 149
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 136
- 210000005253 yeast cell Anatomy 0.000 claims description 128
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 126
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 119
- 239000008103 glucose Substances 0.000 claims description 118
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 117
- 229920001184 polypeptide Polymers 0.000 claims description 116
- 238000000034 method Methods 0.000 claims description 114
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 105
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 103
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 103
- 230000000694 effects Effects 0.000 claims description 86
- 206010028980 Neoplasm Diseases 0.000 claims description 85
- 108700008625 Reporter Genes Proteins 0.000 claims description 80
- 230000012010 growth Effects 0.000 claims description 73
- 102200009432 rs79993407 Human genes 0.000 claims description 62
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 54
- 230000001939 inductive effect Effects 0.000 claims description 52
- 108091026890 Coding region Proteins 0.000 claims description 50
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 44
- 230000001965 increasing effect Effects 0.000 claims description 42
- 238000007747 plating Methods 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 38
- 108700025694 p53 Genes Proteins 0.000 claims description 31
- CYNAPIVXKRLDER-LBPRGKRZSA-N (2s)-2-benzamido-3-(4-hydroxy-3-nitrophenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C=1C=CC=CC=1)C1=CC=C(O)C([N+]([O-])=O)=C1 CYNAPIVXKRLDER-LBPRGKRZSA-N 0.000 claims description 27
- 108010001498 Galectin 1 Proteins 0.000 claims description 27
- 102100021736 Galectin-1 Human genes 0.000 claims description 27
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- 238000012216 screening Methods 0.000 claims description 24
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 23
- 231100000419 toxicity Toxicity 0.000 claims description 22
- 230000001988 toxicity Effects 0.000 claims description 22
- 239000000411 inducer Substances 0.000 claims description 19
- 231100000252 nontoxic Toxicity 0.000 claims description 16
- 230000003000 nontoxic effect Effects 0.000 claims description 16
- 102200140662 rs150293825 Human genes 0.000 claims description 15
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 claims description 14
- 102220573627 Cellular tumor antigen p53_T150A_mutation Human genes 0.000 claims description 14
- 230000030833 cell death Effects 0.000 claims description 14
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 claims description 13
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 claims description 13
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 claims description 13
- 102220584232 Cellular tumor antigen p53_A76T_mutation Human genes 0.000 claims description 11
- 102220574832 Cellular tumor antigen p53_C124R_mutation Human genes 0.000 claims description 11
- 230000003278 mimic effect Effects 0.000 claims description 11
- 102200103953 rs1064795369 Human genes 0.000 claims description 11
- 102220572790 Cellular tumor antigen p53_Q136K_mutation Human genes 0.000 claims description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 10
- 102200103905 rs1555525248 Human genes 0.000 claims description 7
- 102220594227 Cellular tumor antigen p53_C277W_mutation Human genes 0.000 claims description 6
- 102220584226 Cellular tumor antigen p53_W91C_mutation Human genes 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 102220350297 c.362C>G Human genes 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 229940035893 uracil Drugs 0.000 claims description 5
- 101150009006 HIS3 gene Proteins 0.000 claims description 4
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 claims description 4
- 238000011319 anticancer therapy Methods 0.000 claims description 3
- 101710187578 Alcohol dehydrogenase 1 Proteins 0.000 claims 1
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 claims 1
- 102100036788 Tubulin beta-4A chain Human genes 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 154
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 134
- 102000004169 proteins and genes Human genes 0.000 description 78
- 108700028369 Alleles Proteins 0.000 description 77
- 235000018102 proteins Nutrition 0.000 description 70
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 63
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 63
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 63
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 63
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 63
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 62
- 239000013612 plasmid Substances 0.000 description 57
- 230000004568 DNA-binding Effects 0.000 description 53
- 150000001413 amino acids Chemical class 0.000 description 52
- 230000006698 induction Effects 0.000 description 50
- 239000013598 vector Substances 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 46
- 108700000707 bcl-2-Associated X Proteins 0.000 description 42
- 230000006870 function Effects 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 29
- 238000013518 transcription Methods 0.000 description 29
- 230000035897 transcription Effects 0.000 description 29
- 238000003556 assay Methods 0.000 description 27
- 239000012634 fragment Substances 0.000 description 25
- 230000027455 binding Effects 0.000 description 24
- 230000009036 growth inhibition Effects 0.000 description 24
- 239000002609 medium Substances 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 24
- 102200103913 rs1064793881 Human genes 0.000 description 24
- 230000002950 deficient Effects 0.000 description 23
- 238000003752 polymerase chain reaction Methods 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 21
- 239000013613 expression plasmid Substances 0.000 description 19
- 102100028501 Galanin peptides Human genes 0.000 description 18
- 210000004962 mammalian cell Anatomy 0.000 description 18
- 108060001084 Luciferase Proteins 0.000 description 17
- 230000008859 change Effects 0.000 description 17
- 210000005260 human cell Anatomy 0.000 description 17
- 238000013459 approach Methods 0.000 description 16
- 230000037361 pathway Effects 0.000 description 16
- 230000008439 repair process Effects 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 229930024421 Adenine Natural products 0.000 description 15
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 15
- 101150094690 GAL1 gene Proteins 0.000 description 15
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 15
- 229960000643 adenine Drugs 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 238000010367 cloning Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 15
- 206010053759 Growth retardation Diseases 0.000 description 14
- 239000005089 Luciferase Substances 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 102200104027 rs1057520006 Human genes 0.000 description 12
- 102220045016 rs587781757 Human genes 0.000 description 12
- 238000001262 western blot Methods 0.000 description 12
- 102220574829 Cellular tumor antigen p53_S121F_mutation Human genes 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 102200104841 rs730882008 Human genes 0.000 description 11
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 10
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 10
- 108010021466 Mutant Proteins Proteins 0.000 description 10
- 102000008300 Mutant Proteins Human genes 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000001747 exhibiting effect Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 238000001415 gene therapy Methods 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 102100040302 39S ribosomal protein L41, mitochondrial Human genes 0.000 description 9
- 101001104225 Homo sapiens 39S ribosomal protein L41, mitochondrial Proteins 0.000 description 9
- 101000713813 Homo sapiens Quinone oxidoreductase PIG3 Proteins 0.000 description 9
- 108091027981 Response element Proteins 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000007547 defect Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 231100000225 lethality Toxicity 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 230000005757 colony formation Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000001665 lethal effect Effects 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000000717 retained effect Effects 0.000 description 7
- 230000001177 retroviral effect Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 101100351811 Caenorhabditis elegans pgal-1 gene Proteins 0.000 description 6
- 102220583904 Cellular tumor antigen p53_S96P_mutation Human genes 0.000 description 6
- -1 IGF-BP3 Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 231100000518 lethal Toxicity 0.000 description 6
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 102200106056 rs1060501209 Human genes 0.000 description 6
- 102220036358 rs199475824 Human genes 0.000 description 6
- 102220045782 rs587782388 Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000459 effect on growth Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 102200005710 rs121918587 Human genes 0.000 description 5
- 102220258393 rs1445512588 Human genes 0.000 description 5
- 102220205140 rs2228205 Human genes 0.000 description 5
- 102200134242 rs6805421 Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102220575772 Cellular tumor antigen p53_P177H_mutation Human genes 0.000 description 4
- 102220565165 Cellular tumor antigen p53_S240N_mutation Human genes 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 102220535842 Osteocalcin_T123S_mutation Human genes 0.000 description 4
- 108020001027 Ribosomal DNA Proteins 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000002224 dissection Methods 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 102200001382 rs386134210 Human genes 0.000 description 4
- 102200106636 rs587782177 Human genes 0.000 description 4
- 102220058319 rs730881996 Human genes 0.000 description 4
- 102220093743 rs754768271 Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 238000003146 transient transfection Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 3
- 102220575179 Cellular tumor antigen p53_C124Y_mutation Human genes 0.000 description 3
- 102220565169 Cellular tumor antigen p53_N239Y_mutation Human genes 0.000 description 3
- 102220597407 Cellular tumor antigen p53_N288K_mutation Human genes 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 102220490800 Electron transfer flavoprotein subunit alpha, mitochondrial_T123P_mutation Human genes 0.000 description 3
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 101710182846 Polyhedrin Proteins 0.000 description 3
- 102220501404 Putative uncharacterized protein LINC00574_W91R_mutation Human genes 0.000 description 3
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 102220388297 c.406C>A Human genes 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000002230 centromere Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000006481 glucose medium Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000006916 protein interaction Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102200062519 rs121909223 Human genes 0.000 description 3
- 102200108472 rs121912654 Human genes 0.000 description 3
- 102200133387 rs35564486 Human genes 0.000 description 3
- 102200003479 rs397509385 Human genes 0.000 description 3
- 102200105073 rs483352696 Human genes 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 102220523422 Cellular tumor antigen p53_E198V_mutation Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 208000012766 Growth delay Diseases 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102220515405 Olfactory receptor 5W2_M160T_mutation Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 101150080074 TP53 gene Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 102220366963 c.347G>C Human genes 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 230000009643 growth defect Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 238000003468 luciferase reporter gene assay Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 102220248356 rs1057523424 Human genes 0.000 description 2
- 102220052727 rs139854607 Human genes 0.000 description 2
- 102200106429 rs1555525564 Human genes 0.000 description 2
- 102200106066 rs1555525970 Human genes 0.000 description 2
- 102200080081 rs193302888 Human genes 0.000 description 2
- 102200006816 rs200534715 Human genes 0.000 description 2
- 102220262371 rs200810494 Human genes 0.000 description 2
- 102220046402 rs201047375 Human genes 0.000 description 2
- 102200132384 rs28940279 Human genes 0.000 description 2
- 102220055599 rs372134800 Human genes 0.000 description 2
- 102200001463 rs386134198 Human genes 0.000 description 2
- 102200102699 rs587781845 Human genes 0.000 description 2
- 102220087848 rs58917027 Human genes 0.000 description 2
- 102220122704 rs769560800 Human genes 0.000 description 2
- 102220132549 rs886046533 Human genes 0.000 description 2
- 102220136857 rs886055358 Human genes 0.000 description 2
- 102220144332 rs886058543 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102220597440 Cellular tumor antigen p53_E285A_mutation Human genes 0.000 description 1
- 102220574465 Cellular tumor antigen p53_H178Y_mutation Human genes 0.000 description 1
- 102220571915 Cellular tumor antigen p53_M160T_mutation Human genes 0.000 description 1
- 102220574827 Cellular tumor antigen p53_V122L_mutation Human genes 0.000 description 1
- 102220593080 Cellular tumor antigen p53_V274I_mutation Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 230000020172 G2/M transition checkpoint Effects 0.000 description 1
- 102000054184 GADD45 Human genes 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101100135892 Homo sapiens PDIA6 gene Proteins 0.000 description 1
- 101500026142 Homo sapiens Processed cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000002329 Inga feuillei Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 101150045458 KEX2 gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910009891 LiAc Inorganic materials 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100462520 Mus musculus Tp53 gene Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102400000755 Processed cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 101000832889 Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-11545) Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 102000045020 human p5 Human genes 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000010661 induction of programmed cell death Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 101150109301 lys2 gene Proteins 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 101150024228 mdm2 gene Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 102200059338 rs104894332 Human genes 0.000 description 1
- 102200104147 rs1064794311 Human genes 0.000 description 1
- 102200145452 rs121908580 Human genes 0.000 description 1
- 102200106301 rs121912655 Human genes 0.000 description 1
- 102200042810 rs17222744 Human genes 0.000 description 1
- 102200143710 rs2235371 Human genes 0.000 description 1
- 102200106179 rs28934573 Human genes 0.000 description 1
- 102200053893 rs60617604 Human genes 0.000 description 1
- 102200034073 rs78464826 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical compound OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006202361A AU2006202361A1 (en) | 1999-07-30 | 2006-06-02 | Human P53 mutations and a genetic system in yeast for functional identification of human P53 mutations |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14663499P | 1999-07-30 | 1999-07-30 | |
| US60/146634 | 1999-07-30 | ||
| PCT/US2000/020538 WO2001009325A2 (en) | 1999-07-30 | 2000-07-28 | Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006202361A Division AU2006202361A1 (en) | 1999-07-30 | 2006-06-02 | Human P53 mutations and a genetic system in yeast for functional identification of human P53 mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6239500A AU6239500A (en) | 2001-02-19 |
| AU784293B2 true AU784293B2 (en) | 2006-03-02 |
Family
ID=22518261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU62395/00A Ceased AU784293B2 (en) | 1999-07-30 | 2000-07-28 | Human P53 mutations and a genetic system in yeast for functional indentification of human P53 mutations |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1204745A2 (enExample) |
| JP (1) | JP2003506041A (enExample) |
| AU (1) | AU784293B2 (enExample) |
| CA (1) | CA2380631A1 (enExample) |
| WO (1) | WO2001009325A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7256260B1 (en) | 1999-07-30 | 2007-08-14 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, Nih | Human p53 mutations and a genetic system in yeast for functional identification of human p53 mutations |
| AU2008257791B2 (en) * | 2007-05-31 | 2013-03-28 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | P53 peptide vaccine |
| CN110257467A (zh) * | 2019-07-22 | 2019-09-20 | 福州市皮肤病防治院 | 一种检测肿瘤抑制因子p53显性抑制突变的试剂盒及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996016988A1 (en) * | 1994-11-28 | 1996-06-06 | Thomas Jefferson University | Reagents and processes for targeting mutant epidermal growth factor receptors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008049A1 (en) * | 1992-10-01 | 1994-04-14 | The General Hospital Corporation | Functional assay for tumor suppressor genes |
| WO1996016989A1 (en) * | 1994-11-28 | 1996-06-06 | The Wistar Institute Of Anatomy And Biology | p53 PROTEINS WITH ALTERED TETRAMERIZATION DOMAINS |
| US5840579A (en) * | 1996-05-01 | 1998-11-24 | The Johns Hopkins University | Nucleic acids encoding p53 mutations which suppress p53 cancer mutations |
| US6429298B1 (en) * | 1998-10-13 | 2002-08-06 | Board Of Regents, The University Of Texas System | Assays for identifying functional alterations in the p53 tumor suppressor |
| JP2003520023A (ja) * | 1999-05-12 | 2003-07-02 | ゼンコー | ｐ５３活性および変更された四量体化ドメインを有する新規の核酸およびタンパク質 |
-
2000
- 2000-07-28 EP EP00948979A patent/EP1204745A2/en not_active Withdrawn
- 2000-07-28 CA CA002380631A patent/CA2380631A1/en not_active Abandoned
- 2000-07-28 WO PCT/US2000/020538 patent/WO2001009325A2/en not_active Ceased
- 2000-07-28 JP JP2001514117A patent/JP2003506041A/ja active Pending
- 2000-07-28 AU AU62395/00A patent/AU784293B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996016988A1 (en) * | 1994-11-28 | 1996-06-06 | Thomas Jefferson University | Reagents and processes for targeting mutant epidermal growth factor receptors |
Non-Patent Citations (2)
| Title |
|---|
| EMBOJ 17, 1847 913, 5393 * |
| MOL CELL BIOL 15, 5196 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6239500A (en) | 2001-02-19 |
| WO2001009325A3 (en) | 2001-08-30 |
| EP1204745A2 (en) | 2002-05-15 |
| WO2001009325A9 (en) | 2002-08-08 |
| WO2001009325A2 (en) | 2001-02-08 |
| JP2003506041A (ja) | 2003-02-18 |
| CA2380631A1 (en) | 2001-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiao et al. | Interaction between the retinoblastoma protein and the oncoprotein MDM2 | |
| Ziv et al. | Recombinant ATM protein complements the cellular AT phenotype | |
| Pietenpol et al. | Sequence-specific transcriptional activation is essential for growth suppression by p53. | |
| Madaule et al. | A novel partner for the GTP‐bound forms of rho and rac | |
| US5858678A (en) | Apoptosis-regulating proteins | |
| Bruening et al. | Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells | |
| AU1174295A (en) | Bcl-2-associated proteins | |
| WO1995013292A9 (en) | Bcl-2-associated proteins | |
| WO2002064790A2 (en) | Jfy1 protein induces rapid apoptosis | |
| Inga et al. | Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants | |
| Ozaki et al. | Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB | |
| US6218515B1 (en) | Cyclin E variants and use thereof | |
| AU784293B2 (en) | Human P53 mutations and a genetic system in yeast for functional indentification of human P53 mutations | |
| EP1243595B1 (en) | Bh4-fused polypeptides | |
| US7256260B1 (en) | Human p53 mutations and a genetic system in yeast for functional identification of human p53 mutations | |
| WO2001096566A1 (en) | Gasc1 gene | |
| US7919233B2 (en) | Motif of the beclin protein which interacts with anti-apoptotic members of the Bcl-2 protein family, and uses | |
| AU2006202361A1 (en) | Human P53 mutations and a genetic system in yeast for functional identification of human P53 mutations | |
| US20050220781A1 (en) | IFIX, a novel HIN-200 protein, for cancer therapy | |
| Sakai et al. | Interaction of a paraneoplastic cerebellar degeneration-associated neuronal protein with the nuclear helix-loop-helix leucine zipper protein MRG X | |
| WO1997015587A1 (en) | Abl-interactor protein | |
| EP1847607B1 (en) | Antibodies against the p51 protein | |
| US5770720A (en) | Ubiquitin conjugating enzymes having transcriptional repressor activity | |
| US6297019B1 (en) | Recombinant polynucleotides encoding CYP7 promoter-binding factors | |
| WO2003061603A2 (en) | Global suppressors of p53 mutations |